Susceptibility of multiresistant serotype 012 Pseudomonas aeruginosa to fosfomycin in combination with other antibiotics.
Serotype 012 represented 15% of 244 isolates of Pseudomonas aeruginosa isolated in the hospital over a 2 year-period and most isolates of this serotype were resistant to multiple antibiotics. Combination experiments showed that fosfomycin and amikacin together were active against 92% of 012 isolates. It is recommended that serotyping be used systematically to identify 012 strains rapidly and fosfomycin/amikacin be considered as a presumptive antipseudomonal therapy in 012 infections.
Watine
J
J
Laboratoire de Biologie Clinique, CHG, Rodez, France.
Bourrel
C
C
Dubourdieu
B
B
Gineston
J L
JL
Bories
P
P
Durand
M
M
Marre
A
A
Formosa
F
F
Brunel
M P
MP
Palliez
J
J
D042462:4-Quinolones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology; D005578:Fosfomycin / Q000494:pharmacology*; D066298:In Vitro Techniques; D007769:Lactams; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
D042462:4-Quinolones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007769:Lactams; D005578:Fosfomycin